Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2

Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir... INTRODUCTIONHepatitis C virus (HCV) infection is a common cause of chronic liver infection, affecting 170 million individuals worldwide. HCV genotype 2, one of six HCV genotypes, is the third most common genotype in the world and is the cause of 30% of chronic HCV hepatitis in Japan. Chronic HCV infection is a major cause of end‐stage liver disease and hepatocellular carcinoma (HCC). Sustained virological response assessed at 12 weeks posttreatment (SVR12) is associated with a lower rate of morbidity and mortality.Twenty‐four weeks treatment of patients with HCV genotype 2 infection with peg‐interferon (Peg‐IFN) and ribavirin (RBV) has historically yielded favorable SVR rates. However, the clinical application of Peg‐IFN‐based treatment is limited due to poor tolerability, especially in patients with liver cirrhosis. The introduction of the highly efficient direct‐acting antiviral (DAA) drug combination, together with minor side effects and oral use has facilitated the treatment of chronic HCV hepatitis. In 2015, sofosbuvir (SOF), a nucleotide NS5B polymerase inhibitor, with good resistance profile, was approved in Japan for the treatment of patients with HCV genotype 2 hepatitis. However, no report have evaluated predictors of DAA‐treatment efficacy or treatment‐related changes in predictors of early hepatocarcinogenesis, such as α‐fetoprotein (AFP) and liver stiffness http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Medical Virology Wiley

Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2

Loading next page...
 
/lp/wiley/predictors-of-treatment-efficacy-and-liver-stiffness-changes-following-zLOMI1FS3U
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
0146-6615
eISSN
1096-9071
D.O.I.
10.1002/jmv.25023
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONHepatitis C virus (HCV) infection is a common cause of chronic liver infection, affecting 170 million individuals worldwide. HCV genotype 2, one of six HCV genotypes, is the third most common genotype in the world and is the cause of 30% of chronic HCV hepatitis in Japan. Chronic HCV infection is a major cause of end‐stage liver disease and hepatocellular carcinoma (HCC). Sustained virological response assessed at 12 weeks posttreatment (SVR12) is associated with a lower rate of morbidity and mortality.Twenty‐four weeks treatment of patients with HCV genotype 2 infection with peg‐interferon (Peg‐IFN) and ribavirin (RBV) has historically yielded favorable SVR rates. However, the clinical application of Peg‐IFN‐based treatment is limited due to poor tolerability, especially in patients with liver cirrhosis. The introduction of the highly efficient direct‐acting antiviral (DAA) drug combination, together with minor side effects and oral use has facilitated the treatment of chronic HCV hepatitis. In 2015, sofosbuvir (SOF), a nucleotide NS5B polymerase inhibitor, with good resistance profile, was approved in Japan for the treatment of patients with HCV genotype 2 hepatitis. However, no report have evaluated predictors of DAA‐treatment efficacy or treatment‐related changes in predictors of early hepatocarcinogenesis, such as α‐fetoprotein (AFP) and liver stiffness

Journal

Journal of Medical VirologyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off